Gerresheimer achieves record earnings for the financial year 2010

Gerresheimer AG, one of the leading worldwide suppliers to the pharma and healthcare industry, finished the financial year 2010 with record results. “The financial year 2010 was very successful for us. Our know-how and products are very much in demand from international pharma customers. Our shareholders should participate in this success. We therefore propose to the Annual General Meeting a dividend of EUR 0.50 per share”, says Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer achieved a marked increase in revenues in the financial year 2010 (December 1, 2009 to November 30, 2010). Excluding the Technical Plastic Systems business, which was sold in 2009, revenues grew by 5.6% to EUR 1024.8m. At constant exchange rates, revenues grew by 4.0%. The main growth contributors in the pharma business were insulin pens, inhalers vials, ampoules and prefillable syringes. Demand for cosmetics packaging revived markedly in 2010. The market for life science research products also recovered.

Gerresheimer increased its Adjusted EBITDA to EUR 204.5m in 2010. This was 10.0% up on the prior year. The Adjusted EBITDA margin was further improved on a like-for-like basis by 0.8 percentage points on the prior year to 20.0%. Net income reached a record level at EUR 46.7m (prior year EUR 7.0m). Adjusted earnings per share also improved significantly from EUR 1.34 to EUR 1.95.

The marked improvement in operating results also had a positive effect on cash flow. A total of EUR 62.3m was applied to further debt repayments. Net financial debt at the end of the year was therefore at the historically low level of EUR 311.0m.

“In 2010 we achieved our targets and even exceeded some of them. In the coming years we will further expand our position as a full service provider in the important growth markets such as diabetes and generics for example. In doing so the emerging countries play an increasing role. We want to grow our revenues substantially in these markets, and to double them by 2013 to EUR 200m”, Röhrhoff says.


For the financial year 2011 Gerresheimer assumes further revenue growth of 3% to 4% at constant exchange rates. This is equivalent to nominal revenue growth of 4% to 5%. With regard to the EBITDA margin the company assumes a level of around 20%. In 2011 the company expects to invest around EUR 80m. The Management Board proposes to the General Meeting a dividend payment of EUR 0.50 per share for the financial year 2010.

15.02.2011, Gerresheimer AG

Les informations publiées sur notre portail sont soumises au droit d´auteur et appartiennent à la société en question resp. à la source des nouvelles. Tous les droits sont réservés expressément. N´importe quel utilisateur qui accède à un tel matériel peut faire ainsi seulement pour sa propre utilisation personnelle, et l´usage d´un tel matériel est au risque unique de l´utilisateur. La redistribution ou toute autre exploitation commerciale d´un tel matériel de nouvelles est expressément interdite. Là où un tel matériel de nouvelles est fourni par un tiers, chaque utilisateur accepte d´observer et être lié par les limites spécifiques de l´utilisation s´appliquant à un tel matériel de nouvelles. Glass Global ne représente ou n´approuve pas l´exactitude ou la fiabilité d´aucune des informations citées dans les nouvelles ou pages externes auxquelles on se réfère ici.

Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.